Neurodegenerative Diseases Drugs Market Outlook: Size, Share, Trends, Growth Analysis, Competitive Landscape & Forecast, 2026-2033

The Neurodegenerative Diseases Drugs Market size was valued at US$ 61.13 Billion in 2025 and is projected to reach US$ 97.46 Billion by 2033, growing at a CAGR of 6% during 2026–2033, supported by aging populations, expanding neurological disease prevalence, disease-modifying therapy launches, biomarker-led diagnosis, and increasing investment in precision neuroscience.

Report Coverage

Drug Class: Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others
Disease Indication: Multiple Sclerosis, Parkinsonâs Disease, Alzheimer's Disease, Spinal Muscular Atrophy , Others
Route of Administration: Oral, Injection, Transdermal, Others

US$ 61.13 Bn Market size in 2025

US$ 97.46 Bn Market Size by 2033

6.00% CAGR, 2026 - 2033

2026-2033 Forecast Period

Download Sample PDF Buy Now

Format PDF + Excel + PPT

No. of Pages: 350

Category Life Sciences

Report Code: BMIPUB00038445

Last Updated: 2026-08-28

Author

Krishna Sunthwal

Analyst Connect

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Neurodegenerative Diseases Drugs Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Neurodegenerative Diseases Drugs Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Neurodegenerative Diseases Drugs Market Global Analysis

6.2 Neurodegenerative Diseases Drugs Market Revenue 2022-2033 (US$ Billion)

6.3 Neurodegenerative Diseases Drugs Market Forecast Analysis

7. Neurodegenerative Diseases Drugs Market Analysis – by Drug Class

7.1 Immunomodulator

7.1.1 Overview
7.1.2 Immunomodulator: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

7.2 Interferons

7.2.1 Overview
7.2.2 Interferons: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

7.3 Decarboxylase Inhibitors

7.3.1 Overview
7.3.2 Decarboxylase Inhibitors: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

7.4 Dopamine Agonists

7.4.1 Overview
7.4.2 Dopamine Agonists: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

7.5 Others

7.5.1 Overview
7.5.2 Others: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

8. Neurodegenerative Diseases Drugs Market Analysis – by Disease Indication

8.1 Multiple Sclerosis

8.1.1 Overview
8.1.2 Multiple Sclerosis: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

8.2 Parkinsonâs Disease

8.2.1 Overview
8.2.2 Parkinsonâs Disease: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

8.3 Alzheimer's Disease

8.3.1 Overview
8.3.2 Alzheimer's Disease: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

8.4 Spinal Muscular Atrophy

8.4.1 Overview
8.4.2 Spinal Muscular Atrophy : Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

8.5 Others

8.5.1 Overview
8.5.2 Others: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

9. Neurodegenerative Diseases Drugs Market Analysis – by Route of Administration

9.1 Oral

9.1.1 Overview
9.1.2 Oral: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

9.2 Injection

9.2.1 Overview
9.2.2 Injection: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

9.3 Transdermal

9.3.1 Overview
9.3.2 Transdermal: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

9.4 Others

9.4.1 Overview
9.4.2 Others: Neurodegenerative Diseases Drugs Market – Revenue and Forecast, 2022-2033 (US$ Billion)

10. Neurodegenerative Diseases Drugs Market – Geographic Analysis

10.1 Overview

10.2 North America

10.2.1 Neurodegenerative Diseases Drugs Market Breakdown, by Key Country, 2026 and 2033 (%)
10.2.1.1 Neurodegenerative Diseases Drugs Market – Revenue and Forecast Analysis – by Country
10.2.1.1 US: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.2.1.1.1 US: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.2.1.1.2 US: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.2.1.1.3 US: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.2.1.2 Canada: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.2.1.2.1 Canada: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.2.1.2.2 Canada: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.2.1.2.3 Canada: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.2.1.3 Mexico: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.2.1.3.1 Mexico: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.2.1.3.2 Mexico: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.2.1.3.3 Mexico: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3 Europe

10.3.1 Neurodegenerative Diseases Drugs Market Breakdown, by Key Country, 2026 and 2033 (%)
10.3.1.1 Neurodegenerative Diseases Drugs Market – Revenue and Forecast Analysis – by Country
10.3.1.1 Germany: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.1.1 Germany: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.1.2 Germany: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.1.3 Germany: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.2 Italy: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.2.1 Italy: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.2.2 Italy: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.2.3 Italy: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.3 France: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.3.1 France: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.3.2 France: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.3.3 France: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.4 U.K.: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.4.1 U.K.: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.4.2 U.K.: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.4.3 U.K.: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.5 Spain: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.5.1 Spain: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.5.2 Spain: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.5.3 Spain: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.6 Belgium: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.6.1 Belgium: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.6.2 Belgium: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.6.3 Belgium: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.7 Netherlands: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.7.1 Netherlands: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.7.2 Netherlands: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.7.3 Netherlands: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.8 Luxembourg: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.8.1 Luxembourg: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.8.2 Luxembourg: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.8.3 Luxembourg: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.9 Norway: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.9.1 Norway: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.9.2 Norway: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.9.3 Norway: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.10 Finland: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.10.1 Finland: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.10.2 Finland: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.10.3 Finland: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.11 Denmark: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.11.1 Denmark: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.11.2 Denmark: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.11.3 Denmark: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.12 Sweden: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.12.1 Sweden: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.12.2 Sweden: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.12.3 Sweden: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.13 Switzerland: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.13.1 Switzerland: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.13.2 Switzerland: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.13.3 Switzerland: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.14 Austria: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.14.1 Austria: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.14.2 Austria: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.14.3 Austria: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.15 Greece: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.15.1 Greece: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.15.2 Greece: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.15.3 Greece: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.16 Portugal: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.16.1 Portugal: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.16.2 Portugal: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.16.3 Portugal: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.17 Russia: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.17.1 Russia: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.17.2 Russia: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.17.3 Russia: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.18 Poland: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.18.1 Poland: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.18.2 Poland: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.18.3 Poland: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.19 Romania: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.19.1 Romania: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.19.2 Romania: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.19.3 Romania: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.20 Czech Republic: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.20.1 Czech Republic: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.20.2 Czech Republic: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.20.3 Czech Republic: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.21 Ukraine: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.21.1 Ukraine: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.21.2 Ukraine: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.21.3 Ukraine: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.22 Slovakia: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.22.1 Slovakia: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.22.2 Slovakia: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.22.3 Slovakia: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.3.1.23 Bulgaria: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.3.1.23.1 Bulgaria: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.3.1.23.2 Bulgaria: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.3.1.23.3 Bulgaria: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4 Asia-Pacific

10.4.1 Neurodegenerative Diseases Drugs Market Breakdown, by Key Country, 2026 and 2033 (%)
10.4.1.1 Neurodegenerative Diseases Drugs Market – Revenue and Forecast Analysis – by Country
10.4.1.1 China: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.1.1 China: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.1.2 China: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.1.3 China: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.2 Japan: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.2.1 Japan: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.2.2 Japan: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.2.3 Japan: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.3 South Korea: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.3.1 South Korea: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.3.2 South Korea: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.3.3 South Korea: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.4 India: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.4.1 India: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.4.2 India: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.4.3 India: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.5 Australia: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.5.1 Australia: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.5.2 Australia: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.5.3 Australia: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.6 New Zealand: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.6.1 New Zealand: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.6.2 New Zealand: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.6.3 New Zealand: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.7 Indonesia: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.7.1 Indonesia: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.7.2 Indonesia: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.7.3 Indonesia: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.8 Malaysia: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.8.1 Malaysia: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.8.2 Malaysia: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.8.3 Malaysia: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.9 Philippines: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.9.1 Philippines: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.9.2 Philippines: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.9.3 Philippines: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.10 Singapore: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.10.1 Singapore: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.10.2 Singapore: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.10.3 Singapore: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.11 Thailand: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.11.1 Thailand: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.11.2 Thailand: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.11.3 Thailand: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.12 Vietnam: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.12.1 Vietnam: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.12.2 Vietnam: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.12.3 Vietnam: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.13 Taiwan: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.13.1 Taiwan: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.13.2 Taiwan: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.13.3 Taiwan: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.4.1.14 Bangladesh: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.4.1.14.1 Bangladesh: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.4.1.14.2 Bangladesh: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.4.1.14.3 Bangladesh: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.5 South and Central America

10.5.1 Neurodegenerative Diseases Drugs Market Breakdown, by Key Country, 2026 and 2033 (%)
10.5.1.1 Neurodegenerative Diseases Drugs Market – Revenue and Forecast Analysis – by Country
10.5.1.1 Brazil: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.5.1.1.1 Brazil: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.5.1.1.2 Brazil: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.5.1.1.3 Brazil: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.5.1.2 Argentina: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.5.1.2.1 Argentina: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.5.1.2.2 Argentina: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.5.1.2.3 Argentina: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.5.1.3 Chile: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.5.1.3.1 Chile: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.5.1.3.2 Chile: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.5.1.3.3 Chile: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.5.1.4 Colombia: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.5.1.4.1 Colombia: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.5.1.4.2 Colombia: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.5.1.4.3 Colombia: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.5.1.5 Peru: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.5.1.5.1 Peru: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.5.1.5.2 Peru: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.5.1.5.3 Peru: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6 Middle East and Africa

10.6.1 Neurodegenerative Diseases Drugs Market Breakdown, by Key Country, 2026 and 2033 (%)
10.6.1.1 Neurodegenerative Diseases Drugs Market – Revenue and Forecast Analysis – by Country
10.6.1.1 Saudi Arabia: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.1.1 Saudi Arabia: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.1.2 Saudi Arabia: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.1.3 Saudi Arabia: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.2 United Arab Emirates: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.2.1 United Arab Emirates: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.2.2 United Arab Emirates: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.2.3 United Arab Emirates: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.3 Kuwait: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.3.1 Kuwait: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.3.2 Kuwait: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.3.3 Kuwait: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.4 Bahrain: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.4.1 Bahrain: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.4.2 Bahrain: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.4.3 Bahrain: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.5 Qatar: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.5.1 Qatar: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.5.2 Qatar: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.5.3 Qatar: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.6 Oman: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.6.1 Oman: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.6.2 Oman: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.6.3 Oman: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.7 Turkiye: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.7.1 Turkiye: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.7.2 Turkiye: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.7.3 Turkiye: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.8 South Africa: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.8.1 South Africa: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.8.2 South Africa: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.8.3 South Africa: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.9 Egypt: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.9.1 Egypt: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.9.2 Egypt: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.9.3 Egypt: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.10 Nigeria: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.10.1 Nigeria: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.10.2 Nigeria: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.10.3 Nigeria: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

10.6.1.11 Algeria: Neurodegenerative Diseases Drugs Market – Revenue and Forecast to 2033 (US$ Billion)

10.6.1.11.1 Algeria: Neurodegenerative Diseases Drugs Market Breakdown, by Drug Class
10.6.1.11.2 Algeria: Neurodegenerative Diseases Drugs Market Breakdown, by Disease Indication
10.6.1.11.3 Algeria: Neurodegenerative Diseases Drugs Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Biogen Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 F. Hoffmann-La Roche Ltd.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Novartis AG

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Eli Lilly and Company

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Pfizer Inc.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Merck & Co., Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Sanofi S.A.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Teva Pharmaceutical Industries Ltd.

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 UCB S.A.

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Bristol-Myers Squibb Company.

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Access the Full N Market Report

Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.

Download Sample Request Customization